Molecular mechanisms of host-derived CCL5 mediated mammary tumor growth
Molecular mechanisms of host-derived CCL5 mediated mammary tumor growth
批准号:
7989779
负责人:
Jianguo Liu
金额:
$16.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-07 至 2013-08-31
关键词:
Breast Cancer ModelBreast Cancer TreatmentCancer PatientCellsCessation of lifeDataFibroblastsFlow CytometryGoalsGrowthImmunofluorescence ImmunologicImmunologicsInfiltrationInflammationInflammatoryLungMalignant NeoplasmsMammary NeoplasmsMammary glandMediatingMolecularMusNeoplasm MetastasisNorth AmericaPlayProductionProgressive DiseaseRANTESRecruitment ActivityResearchResistanceRoleSignal TransductionSiteStaining methodStainsT cell responseT-LymphocyteTherapeutic AgentsTimeTumor AngiogenesisTumor-DerivedTumor-Secreted ProteinWild Type MouseWomanchemokineeosinophilmacrophagemalignant breast neoplasmneoplastic cellnew therapeutic targetpublic health relevancetumortumor growthtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Breast cancer is the most common type of malignant tumor among women in North America. Higher CCL5 production in breast cancer patients is associated with more progressive disease, indicating an important role of CCL5 in breast cancer progression. Recently, we have found that CCL5 deficient mice are highly resistant to mammary tumor growth and metastasis, with decreased numbers of macrophages infiltrated in the tumor. Therefore, we hypothesize that host CCL5 promotes mammary gland tumor progression by attracting macrophages migrated into the tumor. Blocking CCL5 signaling in a tumor-bearing host may serve as a new therapeutic target for breast cancer treatments. CCL5 is a chemokine produced by a variety of cells, including T cells, macrophages, fibroblasts and tumor cells. It plays an important role in inflammation by recruiting T cells, macrophages and eosinophils to inflammatory sites. CCL5 has been shown to be able to help in tumor angiogenesis, inhibit T cell responses and enhance growth of breast cancers. Using a syngeneic mammary tumor model, a recent study demonstrates that tumor-derived CCL5 is dispensable for tumor progression, suggesting it is the host-derived CCL5 which is important for breast cancer growth and metastasis. Our preliminary data demonstrates that mice genetically deficient in CCL5 (CCL5-KO) are resistant to tumor-induced death and develop few lung metastases. Consistent with these findings, neutralization of CCL5 in wild-type mice suppresses tumor growth and lung metastases. Further analyses of tumors by flow cytometry and immunofluorescence staining reveal a significant decrease of macrophages in the tumors of CCL5-KO mice. Our data provides direct evidence for the first time that host-derived CCL5 is essential for mammary tumor growth and metastasis. Since the mechanisms of host-derived CCL5 in promoting mammary tumor progression are largely unknown, we propose to investigate the mechanisms whereby host-derived CCL5 mediates macrophage infiltration into the tumors and the molecular mechanisms by which tumor cells induce CCL5 expression in host macrophages. Our long-term goal is to elucidate the cellular, molecular and immunologic mechanisms by which host CCL5 promotes breast cancer growth and metastasis, and to ultimately develop therapeutic agents that target CCL5 in a tumor-specific manner.
PUBLIC HEALTH RELEVANCE: Breast cancer is the most common type of malignant tumor among women in North America. Higher CCL5 production in breast cancer patients is associated with more progressive disease, indicating an important role of CCL5 in breast cancer progression. Our goal is to elucidate the cellular, molecular and immunologic mechanisms by which host CCL5 promotes breast cancer growth and metastasis, and to ultimately develop therapeutic agents that target CCL5 in a tumor-specific manner.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of RNA-binding protein in immune evasion of Mtb in macrophages
-
批准号:10634764
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2022
-
负责人:Jianguo Liu
-
依托单位:
Role of RNA-binding protein in immune evasion of Mtb in macrophages
-
批准号:10511464
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2022
-
负责人:Jianguo Liu
-
依托单位:
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
-
批准号:10579334
-
项目类别:
-
资助金额:$21.17万
-
财政年份:2022
-
负责人:Jianguo Liu
-
依托单位:
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
-
批准号:10435975
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2022
-
负责人:Jianguo Liu
-
依托单位:
A new target for host-directed therapy against TB infection
-
批准号:10256733
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2020
-
负责人:Jianguo Liu
-
依托单位:
A new target for host-directed therapy against TB infection
-
批准号:10057563
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2020
-
负责人:Jianguo Liu
-
依托单位:
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus
-
批准号:8445769
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2013
-
负责人:Jianguo Liu
-
依托单位:
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus
-
批准号:8732600
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2013
-
负责人:Jianguo Liu
-
依托单位:
The role of tristetraprolin in control of breast cancer progression
-
批准号:9079413
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2012
-
负责人:Jianguo Liu
-
依托单位:
The role of tristetraprolin in control of breast cancer progression
-
批准号:8221172
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2012
-
负责人:Jianguo Liu
-
依托单位:
The role of tristetraprolin in control of breast cancer progression
-
批准号:8860146
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2012
-
负责人:Jianguo Liu
-
依托单位:
The role of tristetraprolin in control of breast cancer progression
-
批准号:8698343
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2012
-
负责人:Jianguo Liu
-
依托单位:
The role of tristetraprolin in control of breast cancer progression
-
批准号:8542608
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2012
-
负责人:Jianguo Liu
-
依托单位:
Molecular mechanisms of host-derived CCL5 mediated mammary tumor growth
-
批准号:8138487
-
项目类别:
-
资助金额:$17.28万
-
财政年份:2010
-
负责人:Jianguo Liu
-
依托单位:
Molecular mechanisms of host-derived CCL5 mediated mammary tumor growth
-
批准号:8322819
-
项目类别:
-
资助金额:$17.28万
-
财政年份:2010
-
负责人:Jianguo Liu
-
依托单位:
PARP-1 in Juvenile Idiopathic Arthritis-associated IL-10 Promoter Polymorphisms
-
批准号:7911718
-
项目类别:
-
资助金额:$7.33万
-
财政年份:2009
-
负责人:Jianguo Liu
-
依托单位:
PARP-1 in Juvenile Idiopathic Arthritis-associated IL-10 Promoter Polymorphisms
-
批准号:7715077
-
项目类别:
-
资助金额:$7.38万
-
财政年份:2009
-
负责人:Jianguo Liu
-
依托单位:
PARP-1 in Juvenile Idiopathic Arthritis-associated IL-10 Promoter Polymorphisms
-
批准号:8136771
-
项目类别:
-
资助金额:$7.05万
-
财政年份:2009
-
负责人:Jianguo Liu
-
依托单位:
海外基金